PRX Related StreetInsider.com Reports
-
Paulson's Paulson & Co. Shows New Stakes in Aetna (AET), Alpha Natural (ANR), Mead Johnson (MJN)
-
Par Pharma (PRX) Begins U.S. Shipments of Generic Symbyax (LLY)
-
Paulson's Paulson & Co. Remains Mum on Gold in Q3; Likes Pharmas Again, Drops Out of Viacom
-
Whitworth's Relational Investors Ups Abercrombie & Fitch (ANF), Quest Diagnostics (DGX), (more...)
-
ADT (ADT) To Replace Lexmark (LXK), Pentair (PNR) to Replace DeVry (DV) in S&P 500
-
Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder'
-
Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too
-
Wintworth's Relational Investors Q2 13F: Ups ANG, HAR, HPQ, ITW, Cuts OXY, WU, AMAT, CAT
-
UBS Downgrades Par Pharmaceutical (PRX) to Neutral
-
Par Pharmaceutical (PRX) Tops Q2 EPS Vews; Revs Strong
-
Trading Radar for 08/02: Kraft (KFT), LinkedIn (LNKD), Teva Pharma (TEVA), Activision (ATVI) Report
-
Top 10 News Items 7/16-7/20: Bernanke Points to Slower Than Expected Growth; A Wave of Tech Earnings; Marissa Mayer Named New Yahoo! CEO
-
ThinkEquity Downgrades Par Pharmaceutical (PRX) to Hold
-
Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo
-
Stocks Overbought/Oversold on 07/18: (VZ) (STEM) (PPHM) Overbought; (EDU) (ROVI) (TSN) Oversold
-
Somaxon (SOMX) Shares Double on Silenor Settlement, Strong Sales Outlook
-
After-Hours Movers 07/17: (SOMX) (EMC) (VMW) (CSX) Higher; (ROVI) (SBH) (HRZN) (AGNC) Lower
-
Somaxon (SOMX), Mylan (MYL), Par Pharma (PRX) Enter Silenor Settlement
-
Somaxon Pharmaceuticals (SOMX) Announces Settlement Agreement of Silenor Patent; Updates Revenues
-
Leerink Swann Downgrades Par Pharmaceutical (PRX) to Market Perform; Not Expecting Mylan (MYL) To Up The Ante
-
Needham & Company Downgrades Par Pharmaceutical (PRX) to Hold
-
Unusual 11 Mid-Day Movers 07/16: (ALNY) (PRX) (CONM) Higher; (ANR) (AUTH) (VISN) Lower
-
Par Pharmaceutical (PRX) volatility collapses on acquisition by TPG for $1.9B
-
Streetinsider.com's Hot Lunchtime Reads 07/16: (LVS) (QCOM) (MBI) (PRX) (MSFT)
-
Par Pharmaceutical (PRX) Hugs Buyout Price as it Could See Higher Bids
-
Piper Jaffray Downgrades Par Pharmaceutical (PRX) to Neutral
-
Morning Movers 07/16: (PRX) (ALNY) (CONM) Higher; (ANR) (GDI) Lower
-
Notable Mergers and Acquisitions of the Day 07/16: (GSK)/(HGSI) (PRX) (MMUS) (CONM)
-
Buckingham Cuts Par Pharma (PRX) to Neutral
-
Pre-Open Winners 7/16: (PRX) (AUTH) (HGSI) Higher (more...)
-
Par Pharmaceutical (PRX) Peers On Watch After Deal (TEVA) (MYL) (WPI)
-
Par Pharma (PRX) to Be Acquired by TPG for $50/Share in Cash
-
Par Pharmaceutical (PRX) agrees to be acquired by TPG for $50/share
-
Par Pharma's (PRX) Formulations Unit Receives First FDA Approval for Labetalol
-
Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model
-
Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Defending Core Fundamentals Despite Setback From Lovaza Litigation
-
Amarin Corporation plc (AMRN) Ramps on Lovaza News
-
Teva (TEVA), Par Pharma (PRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
-
Amarin Corporation (AMRN) Jumps as Par Pharm (PRX) Falls
-
Par Pharma (PRX) Drops in Afternoon Trading, Now Down ~7%
-
Whitworth's Relational Investors Shows New Stakes in Abercrombie (ANF), PepsiCo (PEP), Western Union (WU)
-
UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call
-
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Generic Core Delivers; Substantial Upside with Lovaza on Horizon
-
Par Pharmaceutical (PRX) Tops Q1 EPS by 8c
-
Trading Radar for 05/08: Walt Disney (DIS), Fossil (FOSL), Wendy's (WEN), Vitamin Shoppe (VSI), OfficeMax (OMX) Report
-
Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Healthy Deal with Handa
-
Piper Jaffray Starts Par Pharmaceutical (PRX) at Overweight
-
Piper Jaffray Starts Par Pharmaceutical (PRX) at Overweight
-
Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX
-
URL Pharma Sues Par (PRX); Alleges Infringement of Colcrys Patents
Back to PRX Stock Lookup
